Skip to main content
Hit enter to search or ESC to close
Close Search
MedincellMedincellMedincell
search
Menu
  • About Us
    • Impact companyPurposeful innovation coupled with a responsible company model can positively impact Global Health
    • Our peopleOur strength: valuing and nurturing our team’s entrepreneurial spirit, expertise, and dedication
    • Leadership TeamSeasoned leaders unite to tackle global health challenges
  • Science
    • UZEDY®Relapse prevention long-acting treatment for schizophrenia
    • R&D PipelineAdvancing therapeutic care with precision Delivery
    • BEPO® TechnologyOur technology platform to develop long-acting treatments
    • PublicationsFacilitate collaboration with our collection of scientific articles and presentations
  • Responsibility
    • Our commitmentsTransforming global health with purposeful innovation
    • Code and policiesHigh standards for all company’s stakeholders
    • 2026 ESG reportSocial and environmental information about the company and its activities
  • Careers
    • Our vision & our valuesSee how our HR vision and values shape a dynamic workforce
    • Work environment & benefitsExplore the benefits and environment driving our team’s success
    • Join usEmbark on a career journey where your talents meet opportunity
  • News & events
    • NewsroomLatest updates and announcements, the gateway to all press releases
    • EventsEarnings calls, conferences, General Meeting: live and replay
  • Investors
    • OverviewAll information and news about Medincell stock
    • Reports & regulated informationFinancial reports, operational updates, and shareholder information
    • General MeetingAll documents related to the Medincell Shareholders’ Meetings
    • Leadership teamSeasoned leaders unite to tackle global health challenges
  • Contact
  • EN
  • FR
  • search
Category

General

Increase in the Amount Allocated to the Liquidity Contract

April 15, 2025
April 15, 2025

Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI

March 31, 2025
March 31, 2025

Medincell Strengthens its Board of Directors

March 6, 2025
March 6, 2025

Presentation at the TD Cowen 45th Annual Healthcare Conference

February 26, 2025
February 26, 2025

FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder

February 25, 2025
February 25, 2025

Medincell Announces Successful c.€43 Million Global Offering

February 19, 2025

Medincell launches a Global Offering for approximately 10% of its share capital

February 18, 2025

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia

February 10, 2025
February 10, 2025

The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement

February 6, 2025

UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization

January 29, 2025
  • Previous
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 22
  • Next

Articles récents

  • Videoconference • Annual results 2025-26
  • Medincell’s Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
  • Medincell to Participate in Upcoming Investor Conferences
  • Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
  • Medincell appoints Edna Venneker, MD, as Chief Medical Officer

Commentaires récents

No comments to show.

About us

Impact company
Our people
Leadership Team

Science

UZEDY®
R&D Pipeline
BEPO® Technology
Publications

Careers

Our vision & our values
Work environment & benefits
Join us

Responsability

Our commitments
Code and policies
2026 ESG report

News & events

Newsroom
Events

Investors

Overview
Reports & regulated information
General Meeting
Leadership team

Ressources & contact

Contact
Ethics line
Legal notices
Privacy policy

© 2026 Medincell. All rights reserved.

Website by ScreenUp

Close Menu
  • Home
  • About Us
    • Impact company
    • Our people
    • Leadership team
  • Science
    • UZEDY®
    • R&D Pipeline
    • BEPO® Technology
    • Publications
  • Responsibility
    • Our commitments
    • Code and policies
    • 2025 ESG Report
  • Careers
    • Our vision & our values
    • Work environment & benefits
    • Join us
  • News & events
    • News
    • Events
  • Investors
    • Overview
    • Regulated information
    • General Meeting
    • Leadership team
  • Contact
  • FR